In recent years, treatment of infectious disease through Novel Drug delivery system (NDDS) has undergone a revolutionary shift. Niosomes are a Novel Drug Delivery system which has potential application to treat infectious disease topically. Niosomes are non-ionic surfactant vesicles, in which medication is encapsulated in a vesicle for controlled drug release. Ketoconazole niosomes were prepared by using Cholesterol, Span 60/ Span 40 as surfactants, chloroform, and diethyl ether using rotary vacuum evaporator method. Formulation was then evaluated for particle size, drug content, entrapment efficiency, and in-vitro drug release studies. The Entrapment efficiency and drug content were calculated at 225nm using UV spectrophotometer. The drug content was found to be 70.37% for Span 40 and 72.81% for Span 60.The percentage of drug entrapment in niosomes was 60.3 % for Span 40 and 62.21 % for Span 60. FT-IR studies for niosomes containing Span 40 shows -CH stretching (Aliphatic) at 2891 cm -1 and2925 cm -1 for niosomes containing Span 60. Ketoconazole niosomal gel was prepared using Carbopol 940, glycerol, Triethanolamine and distilled water. Evaluation of niosomal gel was determined by Physical appearance, pH, viscosity, drug content, entrapment efficiency and In-vitro permeation studies.The percentage of the drug release from the niosomal gel was found to be 40.78 % for Span 40 and 33.75% for Span 60 . This delivery system is cost effective and simple to prepare as only the prepared gel of niosomes was introduced in Rotary vacuum evaporator for solvent evaporation.
INTRODUCTION
rom last few decades, Novel Drug Delivery system have attracted a considerable attention due to their targeted drug delivery and controlled release of drug. 1 Niosomes are such example of novel drug delivery system in which drug is encapsulated in a vesicle to enhance the bioavailability of drug. 2 Niosomes are made of nonionic surfactant of the alkyl or dialkyl polyglycerol ether class and Cholesterol with subsequent hydration in aqueous media. Niosomes are lamellar structures that are microscopic in size. 3 Niosomes are one of the promising drug carriers that have a bilayer structure. Niosomes attracts much attention because of its advantages in many aspects, such as chemical stability, high purity, content uniformity, low cost, convenient storage of non-ionic surfactants, and large numbers of surfactants available for the design of niosomes. 4 Niosomes increase the stability of entrapped drug, therapeutic performance of the drug molecules and protecting drug from biological environment and restricting effects to target cells. 5 Permeability, chemical and physical approaches are the major barrier for a novel drug delivery system. A number of antifungal agents are available in different topical preparations (e.g., creams, ointments, and powders for the purpose of local dermatological therapy). Antifungal drugs are lipophilic compounds, which are practically insoluble in water and having low permeability to stratum corneum. 
Formulation of Ketoconazole Niosomes
Niosomes were prepared using Reverse phase evaporation technique. Drug, non-ionic surfactant (Span 40, 60) and cholesterol were weighed accurately and dissolved in sufficient amount of solvent mixture (Chloroform: Methanol 2:1) to give a clear solution. The mixture formed was then poured in to 1000ml of rotary flask and evaporated under vacuum (20-25mm Hg) at 60°±2°C with the rotation speed of 100 rpm to form a uniform thin dry film. Further, the rotary flask was removed and allowed to return the temperature to room temperature. The thin film formed was hydrated using 20ml of distilled water while rotating the flask under 50rpm and temperature 60°±2°C. The niosomal suspension was then formed completely and allowed to stored in refrigerator in a tightly closed container.
7 Table: 1 Formulation Code of Niosomes containing surfactant SPAN 40 
EVALUATION OF KETOCONAZOLE NIOSOMES

Particle size analysis
The average particle size of the niosomes was characterize using Malvern's zeta sizer. The niosomal suspension was diluted, filled in a cuvette using suitable blank. 8 
Scanning electron microscopy
Scanning electron microscope was used to determine the sizes of the vesicles. 
Drug content analysis
Drug content in the niosomal suspension equivalent to 100mg was determined by lysing the niosomes using npropanol. 1ml of the lysed niosomal solution was then diluted upto 10ml using 7.4 phosphate buffer. The absorbance of the dilution was then calculated spectrophotometrically at 225nm. 10 
Entrapment efficiency
The free drug concentration in the supernatant was determined at 225 nm using UV-Visible Spectrophotometer after centrifuging 1 ml of the suspension diluted to 10 ml with distilled water at 15,000 rpm for 60 minutes at 4°C using a high speed cooling centrifuge so as to separate niosomes from unentrapped drug. The % drug entrapment was calculated from the following formula. 
FORMULATION OF KETOCONAZOLE NIOSOMAL GEL
Niosomal suspension (10ml) containing ketoconazole equivalent to 2% w/w was incorporated into the gel base composed of Carbopol 940 (1.5%), Glycerol (10%), Triethanolamine (q.s.) and distilled water up to 15ml.
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EVALUATION OF KETOCONAZOLE NIOSOMAL GEL (9) Physical Appearance Clarity, color, homogeneity and the presence of foreign particles in the niosomal gel was determined. pH pH of the niosomal gel was determined using digital pH meter.
Viscosity
Brookfield viscometer was used to determine the viscosity of the niosomal gel.
Drug content uniformity
Drug content of the niosomal gel was calculated by dissolving 10mg of the drug in 100 ml of volumetric flask and suitable volume with 50% n-propanol was formed for lysis of the niosomes. The volume was made up to 100ml using methanol. The solution was then filtered and absorbance was measured under UV spectrophotometer at 225 nm.
Entrapment Efficiency 11
The free drug concentration in the supernatant was determined at 225 nm using UV-Visible Spectrophotometer by centrifuging 0.5 g of the gel equivalent to 10mg of ketoconazole diluted to 10 ml with distilled water at 15,000 rpm for 60 minutes at 4°C using a high speed cooling centrifuge so as to separate the niosomes from the unentrapped drug. The % drug entrapped was calculated from the formula: 
In-vitro drug diffusion studies:
In-vitro diffusion studies of the niosomal gel were carried out using dialysis membrane. The drug release from the niosomal gel was determined from the collected samples. The analysis of the collected samples was done under UV spectrophotometer at 225 nm.
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Stability studies
Stability studies of the different formulations were carried out under different temperature conditions so as to check the effect on: physical appearance, entrapment efficiency and drug content. The niosomal formulations were stored at 2-8°C and at room temperature (30±2°C) in air tight containers for 30 days and 2 ml samples were withdrawn every 15 days and at the end of 45 days. The analysis of the samples was then done spectrophotometrically at 225 nm after lyses of the niosomes and further preparing their suitable dilutions. (13) 
RESULTS AND DISCUSSIONS
Particle size analysis
The average particle size of KTZ 40-3 formulation was found to be 272.3 nm.
The average particle size of KTZ 60-3 formulation was found to be 226.3 nm. 
Drug content and Entrapment Efficiency
Evaluation of Ketoconazole niosomal gel
Physical appearance:
The formed gel is off-white in color. The gel was observed to be bit sticky in nature.
pH:
The pH of the gel formulations were found to be in the range of 6.7 to 6.9. 
KTZ 60-3 8675
Drug content analysis:
The percentage drug content of the formulations were mentioned in the table as follows; Entrapment Efficiency:
The entrapment efficiency of the different gel formulations are as follows; Figure: 3 In-vitro permeation study of ketoconazole Niosomal gel. 
Stability Studies
CONCLUSION
It is concluded that Reverse phase evaporation technique is a useful method for the successful incorporation of poorly water soluble drug Ketoconazole into niosomes with high entrapment efficiency. The prolonged release of the drug from the niosome suggests that the frequency of administration and adverse effects significantly thereby improving the patient compliance. The administration of drug as gel type formulation enhances its penetration.
Both of the batches that is Span 40 and Span 60 were successfully formulated as niosomal gel but Span 40 batch shows an excellent result in the release of drug shown in in vitro permeation studies graph.
